Nanobiotix SA (NBTX) Stock Analysis
Verdict: WATCH (do not buy)
Recent 1,178% surge has detached from fundamental value; J&J data validates the tech, but 2028 profitability remains a distant promise.
Investment score: 44/100
Analysis as of
Is Nanobiotix SA stock worth reviewing? The TradeMates thesis
Nanobiotix is a clinical-stage play with validated technology but a broken capital structure and an unsustainable recent price parabolic move.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Nanobiotix SA opportunities and risks
What speaks for NBTX
- Validation by Johnson & Johnson (J&J)
What speaks against NBTX
- Immediate Dilution Risk
Peers and competitors
- ABVX.PA
- NANO.PA
- DBV.PA
- IVA.PA
- VLA.PA
Frequently asked questions about Nanobiotix SA (NBTX)
Is NBTX stock a good investment?
The TradeMates model rates Nanobiotix SA as WATCH (do not buy) with an investment score of 44/100. Nanobiotix is a clinical-stage play with validated technology but a broken capital structure and an unsustainable recent price parabolic move. This is algorithmic model output, not personal investment advice.
Is NBTX stock a buy?
The TradeMates model verdict for NBTX is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.